Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Posttransplant Cyclophosphamide for Prevention of Chronic GVHD
NCT01427881Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Sep 2011
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide in graft-versus-host disease (GVHD), sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Chronic Graft-versus-Host Disease Requiring Systemic Immunosuppressive Treatment at 1 year. Started Sep 2011; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT01427881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01427881.